Research
The Thoracic Center
(732) 235-7802 • (732) 235-8150 (fax)
Research
New Jersey Cancer Trial Connect
Hundreds of cancer clinical research trials are underway in New Jersey. However, only three to five percent of adult cancer patients participate in these trials. One challenge for those who may be interested is simply finding the trials.
New Jersey Cancer Trial Connect, a web-based resource for healthcare providers and cancer patients, was launched in April 2003 to enable people to identify active clinical trials that may be appropriate treatment options.
Operated by the Cancer Institute of New Jersey with support from the state of New Jersey, the service contains trial information provided by hospitals, academic institutions, oncology offices, and pharmaceutical companies.
New Jersey Cancer Trial Connect enables people with cancer, their families and caregivers to enter specific information about their cancer diagnosis and treatment history.
The system will then search its database to find a clinical trial “match.” Patients are notified electronically when new clinical trials become available. Visit www.njctc.org to learn more or call 1-866-788-3929.
National Cancer Institute(NCI)/National Institutes of Health (NIH) Study Entitled “The Role of a Bone Morphogenetic Protein in Cancer”
One of the biggest problems physicians face in treating lung cancer is patients frequently present with advanced metastatic disease. When lung cancer is detected early, a high cure rate can be expected. Therefore, if lung cancer is detected early and the continued spread of cancer controlled, significant improvements in survival would be expected. Dr. Langenfeld has identified genes which are expressed in lung cancer and not normal lung cells. His research is analyzing whether these genes can be used to detect cancer at an earlier stage and whether inhibition of these genes will decrease cancer spread.
In addition to thoracic surgery, Dr. Langenfeld’s fellowship at Memorial Sloan-Kettering Cancer Center in New York included the conduct of basic science research. The goal of his basic science research is to translate the knowledge of the lung cancer growth into meaningful therapeutic modalities.
Dr. Langenfeld is the recipient of a competitive grant from NCI/NIH to study the role of a bone morphogenetic protein in lung cancer. His work is conducted in his lab within the Clinical Academic Building of UMDNJ-Robert Wood Johnson Medical School.
 |
Dr. Langenfeld was one of two investigators awarded a one-year grant from the New Jersey Commission on Cancer Research (NJCCR) in 2001. Established in 1983, the NJCCR promotes and funds significant cancer research projects carried out by New Jersey scientists. The Commission funds scientifically peer-reviewed cancer research grants and training fellowships at eligible nonprofit institutions throughout the state of New Jersey. Awards are based on the highest scientific merit using a peer-review process similar to the National Cancer Institute and the American Cancer Society.
(732) 235-7802 • (732) 235-8150 (fax)
Print this page